
Przewidywanie ciężkości COVID-19
Julian
- 0
Przewidywanie ciężkości COVID-19 za pomocą swoistego przeciwciała nukleokapsydowego i wskaźnika czynnika ryzyka choroby
Efficient strategies for predicting COVID-19 illness trajectories are urgently wanted. Right here, enzyme-linked immunosorbent assay (ELISA) and coronavirus antigen microarray (COVAM) evaluation mapped antibody epitopes within the plasma of COVID-19 sufferers (n = 86) experiencing a variety of illness states. The experiments recognized antibodies to a 21-residue epitope from nucleocapsid (termed Ep9) related to extreme illness, together with admission to the intensive care unit (ICU), requirement for ventilators, or demise.
Importantly, anti-Ep9 antibodies will be detected inside 6 days post-symptom onset and generally inside 1 day. Moreover, anti-Ep9 antibodies correlate with varied comorbidities and hallmarks of immune hyperactivity. We introduce a simple-to-calculate, illness threat issue rating to quantitate every affected person’s comorbidities and age. For sufferers with anti-Ep9 antibodies, scores above 3.Zero predict extra extreme illness outcomes with a 13.42 chance ratio (96.7% specificity).
The outcomes lay the groundwork for a brand new sort of COVID-19 prognostic to permit early identification and triage of high-risk sufferers. Such info might information more practical therapeutic intervention.IMPORTANCE The COVID-19 pandemic has resulted in over two million deaths worldwide. Regardless of efforts to struggle the virus, the illness continues to overwhelm hospitals with severely unwell sufferers.
Prognosis of COVID-19 is instantly completed by a mess of dependable testing platforms; nonetheless, prognostic prediction stays elusive. To this finish, we recognized a brief epitope from the SARS-CoV-2 nucleocapsid protein and likewise a illness threat issue rating primarily based upon comorbidities and age. The presence of antibodies particularly binding to this epitope plus a rating cutoff can predict extreme COVID-19 outcomes with 96.7% specificity.

IGF BP3 antibody |
|||
70R-IR022 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Rabbit polyclonal IGF BP3 antibody |
IGF BP5 antibody |
|||
70R-IR023 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Rabbit polyclonal IGF BP5 antibody |
IGF BP7 antibody |
|||
70R-IR024 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Rabbit polyclonal IGF BP7 antibody |
IGF BP2 protein |
|||
30R-AI105 | Fitzgerald | 20 ug | EUR 327.6 |
Description: Purified recombinant Human IGF BP2 protein |
IGF BP6 protein |
|||
30R-AI106 | Fitzgerald | 25 ug | EUR 327.6 |
Description: Purified recombinant Human IGF BP6 protein |
IGF BP7 protein |
|||
30R-AI120 | Fitzgerald | 25 ug | EUR 327.6 |
Description: Purified recombinant Human IGF BP7 protein |
IGF BP1 protein |
|||
30R-AI121 | Fitzgerald | 25 ug | EUR 327.6 |
Description: Purified recombinant Human IGF BP1 protein |
IGF BP3 protein |
|||
30R-AI122 | Fitzgerald | 25 ug | EUR 327.6 |
Description: Purified recombinant Human IGF BP3 protein |
IGF BP5 protein |
|||
30R-AI124 | Fitzgerald | 25 ug | EUR 327.6 |
Description: Purified recombinant Human IGF BP5 protein |
IGF-BP3, Human |
|||
HY-P7020 | MedChemExpress | 10ug | EUR 280.8 |
IGF-BP5, Human |
|||
HY-P7021 | MedChemExpress | 50ug | EUR 721.2 |
IGF-BP3, human |
|||
RC216-12B3 | Bio Basic | 5ug | EUR 125.26 |
IGF-1, Human |
|||
HY-P7018 | MedChemExpress | 10ug | EUR 129.6 |
IGF-2, Human |
|||
HY-P7019 | MedChemExpress | 100ug | EUR 432 |
IGF-1, human |
|||
RC216-12 | Bio Basic | 1mg | EUR 451.5 |
Antibody for Human IGF-1 |
|||
SPC-699D-ALP | Stressmarq | 0.1mg | EUR 472.8 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Alkaline Phosphatase. |
Antibody for Human IGF-1 |
|||
SPC-699D-DY350 | Stressmarq | 0.1mg | EUR 496.8 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 350. |
Antibody for Human IGF-1 |
|||
SPC-699D-DY405 | Stressmarq | 0.1mg | EUR 483.6 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 405. |
Antibody for Human IGF-1 |
|||
SPC-699D-DY488 | Stressmarq | 0.1mg | EUR 471.6 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 488. |
Antibody for Human IGF-1 |
|||
SPC-699D | Stressmarq | 0.1mg | EUR 424.8 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is unconjugated. |
Antibody for Human IGF-1 |
|||
SPC-699D-A390 | Stressmarq | 0.1mg | EUR 481.2 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 390. |
Antibody for Human IGF-1 |
|||
SPC-699D-A488 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 488. |
Antibody for Human IGF-1 |
|||
SPC-699D-A565 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 565. |
Antibody for Human IGF-1 |
|||
SPC-699D-A594 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 594. |
Antibody for Human IGF-1 |
|||
SPC-699D-A633 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 633. |
Antibody for Human IGF-1 |
|||
SPC-699D-A655 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 655. |
Antibody for Human IGF-1 |
|||
SPC-699D-A680 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 680. |
Antibody for Human IGF-1 |
|||
SPC-699D-A700 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 700. |
Antibody for Human IGF-1 |
|||
SPC-699D-APC | Stressmarq | 0.1mg | EUR 478.8 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC . |
Antibody for Human IGF-1 |
|||
SPC-699D-APCCY7 | Stressmarq | 0.1mg | EUR 565.2 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC/Cy7. |
Antibody for Human IGF-1 |
|||
SPC-699D-BI | Stressmarq | 0.1mg | EUR 475.2 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Biotin. |
Antibody for Human IGF-1 |
|||
SPC-699D-DY594 | Stressmarq | 0.1mg | EUR 474 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 594. |
Antibody for Human IGF-1 |
|||
SPC-699D-DY633 | Stressmarq | 0.1mg | EUR 468 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 633. |
Antibody for Human IGF-1 |
|||
SPC-699D-FITC | Stressmarq | 0.1mg | EUR 470.4 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to FITC. |
Antibody for Human IGF-1 |
|||
SPC-699D-HRP | Stressmarq | 0.1mg | EUR 465.6 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to HRP. |
Antibody for Human IGF-1 |
|||
SPC-699D-P594 | Stressmarq | 0.1mg | EUR 488.4 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PE/ATTO 594. |
Antibody for Human IGF-1 |
|||
SPC-699D-PCP | Stressmarq | 0.1mg | EUR 478.8 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PerCP. |
Antibody for Human IGF-1 |
|||
SPC-699D-RPE | Stressmarq | 0.1mg | EUR 476.4 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to RPE . |
Antibody for Human IGF-1 |
|||
SPC-699D-STR | Stressmarq | 0.1mg | EUR 477.6 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Streptavidin. |
Antibody for Human IGF-1 |
|||
SPC-699S | Stressmarq | 0.012mg | EUR 78 |
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is unconjugated. |
Human Salivary IGF(salivary IGF) ELISA Kit |
|||
QY-E05383 | Qayee Biotechnology | 96T | EUR 433.2 |
Human IGF-1 LR3 |
|||
SP-89927-100 | Alpha Diagnostics | 100 ug | EUR 270 |
Anti-Rat IGF-1 Antibody |
|||
5121-100 | Biovision | each | EUR 379.2 |
Anti-Rat IGF-1 Antibody |
|||
5121-30T | Biovision | each | EUR 175.2 |
IGF-BP2, human recombinant |
|||
7165-10 | Biovision | each | EUR 301.2 |
IGF-BP2, human recombinant |
|||
7165-50 | Biovision | each | EUR 1123.2 |
IGF-BP7, human recombinant |
|||
7167-10 | Biovision | each | EUR 248.4 |
IGF-BP7, human recombinant |
|||
7167-50 | Biovision | each | EUR 810 |
IGF-BP6, human recombinant |
|||
7350-20 | Biovision | each | EUR 444 |
IGF-BP1, human recombinant |
|||
4717-100 | Biovision | each | EUR 744 |
IGF-BP1, human recombinant |
|||
4717-1000 | Biovision | each | EUR 3778.8 |
IGF-BP1, human recombinant |
|||
4717-25 | Biovision | each | EUR 307.2 |
IGF-BP3, human recombinant |
|||
4720-100 | Biovision | each | EUR 744 |
IGF-BP3, human recombinant |
|||
4720-1000 | Biovision | each | EUR 3778.8 |
IGF-BP3, human recombinant |
|||
4720-25 | Biovision | each | EUR 307.2 |
IGF-BP5, human recombinant |
|||
4723-100 | Biovision | each | EUR 744 |
IGF-BP5, human recombinant |
|||
4723-1000 | Biovision | each | EUR 3778.8 |
IGF-BP5, human recombinant |
|||
4723-25 | Biovision | each | EUR 307.2 |
Recombinant Human IGF-1 |
|||
HEGFP-0901 | Cyagen | 100ug | Ask for price |
Recombinant Human IGF-2 |
|||
HEGFP-0908 | Cyagen | 10ug | Ask for price |
Human IGF-I monoclonal antibody |
|||
MAM1 | GroPep | 500 µg | EUR 358.8 |
IGF-1, human recombinant |
|||
P1016-.02 | ApexBio | 20 µg | EUR 309.6 |
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue |
IGF-1, human recombinant |
|||
P1016-.1 | ApexBio | 100 µg | EUR 915.6 |
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue |
rec IGF-I (human) |
|||
H-5555.0050 | Bachem | 50.0µg | EUR 290.4 |
Description: CAS# [67763-96-6] |
rec IGF-I (human) |
|||
H-5555.0100 | Bachem | 100.0µg | EUR 457.2 |
Description: CAS# [67763-96-6] |
rec IGF-I (human) |
|||
H-5555.0500 | Bachem | 0.5mg | EUR 1720.8 |
Description: CAS# [67763-96-6] |
Human IGF-I Protein |
|||
abx060791-100ug | Abbexa | 100 ug | EUR 560.4 |
Biotinyl Human IGF-I |
|||
AQU010 | GroPep | 10 µg | EUR 303.6 |
Biotinyl Human IGF-I |
|||
AQU050 | GroPep | 50 µg | EUR 415.2 |
Biotinyl Human IGF-I |
|||
AQU100 | GroPep | 100 µg | EUR 637.2 |
Biotinyl Human IGF-I |
|||
AQU500 | GroPep | 500 µg | EUR 1305.6 |
Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-1mg |
|||
QP8601-ec-1mg | EnQuireBio | 1mg | EUR 1958.4 |
Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-10ug |
|||
QP8601-ec-10ug | EnQuireBio | 10ug | EUR 240 |
Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-50ug |
|||
QP8601-ec-50ug | EnQuireBio | 50ug | EUR 315.6 |
Human [Ala31] IGF-I |
|||
AIU020 | GroPep | 20 µg | EUR 303.6 |
Human [Ala31] IGF-I |
|||
AIU100 | GroPep | 100 µg | EUR 415.2 |
Human [Leu60] IGF-I |
|||
ABU020 | GroPep | 20 µg | EUR 303.6 |
Human [Leu60] IGF-I |
|||
ABU100 | GroPep | 100 µg | EUR 415.2 |
Human [Arg6] IGF-II |
|||
GU020 | GroPep | 20 µg | EUR 303.6 |
Human [Leu24] IGF-I |
|||
ZU020 | GroPep | 20 µg | EUR 303.6 |
Human [Leu24] IGF-I |
|||
ZU100 | GroPep | 100 µg | EUR 415.2 |
Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-100ug |
|||
QP8601-ec-100ug | EnQuireBio | 100ug | EUR 489.6 |
Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-200ug |
|||
QP8601-ec-200ug | EnQuireBio | 200ug | EUR 760.8 |
Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-500ug |
|||
QP8601-ec-500ug | EnQuireBio | 500ug | EUR 1272 |
Human [Leu27]IGF-II |
|||
TU100 | GroPep | 100 µg | EUR 415.2 |
Human IGF-2 ELISA Kit |
|||
EHI0307 | Abclonal | 96Tests | EUR 625.2 |
Human IGF-1 ELISA Kit |
|||
RK00160 | Abclonal | 96 Tests | EUR 625.2 |
Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-1mg |
|||
QP5264-1mg | EnQuireBio | 1mg | EUR 1513.2 |
Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-10ug |
|||
QP5264-10ug | EnQuireBio | 10ug | EUR 163.2 |
Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-50ug |
|||
QP5264-50ug | EnQuireBio | 50ug | EUR 284.4 |
Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-100ug |
|||
QP5264-100ug | EnQuireBio | 100ug | EUR 435.6 |
Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-500ug |
|||
QP5264-500ug | EnQuireBio | 500ug | EUR 914.4 |
Recombinant Human IGF-BP1 Protein |
|||
PROTP08833-1 | BosterBio | 25ug | EUR 380.4 |
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP1 is a 25.4 kDa cysteine-rich secreted protein expressed in liver, deciduas, and kidneys and is the most abundant IGF-BP in amniotic fluid. Levels of IGF-BP1 in serum are lowest after food. IGF-BP1 binds to both IGF-I and IGF-II with equal affinity. Phosphorylated IGF-BP1 hinders IGF actions, where as nonphosphorylated IGF-BP1 is stimulatory. Recombinant human IGF-BP1 is a 25.4 kDa protein consisting of 235 amino acid residues (Isoform A). |
Recombinant Human IGF-BP3 Protein |
|||
PROTP17936-2 | BosterBio | 25ug | EUR 380.4 |
Description: IGF-BP3 is a 30 kDa cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals and it is also found in α-granules of platelets. In addition to its ability to modulate the activity of IGF-I and IGF-II, IGF-BP3 exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. Recombinant human IGF-BP3 is a 28.8 kDa protein consisting of 264 amino acid residues. |
Recombinant Human IGF-BP2 Protein |
|||
PROTP18065 | BosterBio | 20ug | EUR 380.4 |
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP2 is a cysteine-rich secreted protein produced by bone cells, and is most abundant in the brain. IGF-BP2 has been shown to inhibit IGF-II action in human breast and ovarian carcinoma cells. Recombinant human IGF-BP2 is a 31.5 kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. *Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc. |
Recombinant Human IGF-BP6 Protein |
|||
PROTP24592-2 | BosterBio | 20ug | EUR 380.4 |
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions. *Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc. |
Recombinant Human IGF-BP5 Protein |
|||
PROTP24593-1 | BosterBio | 25ug | EUR 380.4 |
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP5 is a 28.6 kDa cysteine-rich secreted protein produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. Data shows that IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition and retarded muscle development. Recombinant human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues. |
Recombinant Human IGF-BP7 Protein |
|||
PROTQ16270-2 | BosterBio | 25ug | EUR 380.4 |
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues. |
IGF-1, DES1-3, human |
|||
RC216-12B | Bio Basic | 100ug | EUR 203.56 |
IGF-1 (human) ELISA Kit |
|||
K4775-100 | Biovision | 100 assays | EUR 970.8 |
Description: Sensitive, Colorimetric Assay |
IGF-1 ELISA KIT|Human |
|||
EF000135 | Lifescience Market | 96 Tests | EUR 826.8 |
IGF-2 ELISA KIT|Human |
|||
EF000742 | Lifescience Market | 96 Tests | EUR 826.8 |
IGF-I, human recombinant |
|||
4119-100 | Biovision | each | EUR 210 |
IGF-I, human recombinant |
|||
4119-1000 | Biovision | each | EUR 411.6 |
IGF-I, human recombinant |
|||
4119-10MG | Biovision | each | EUR 1834.8 |
IGF-I, human recombinant |
|||
4119-1G | Biovision | each | EUR 49388.4 |
IGF-I, human recombinant |
|||
4119-20MG | Biovision | each | EUR 2793.6 |
IGF-I, human recombinant |
|||
4119-5000 | Biovision | each | EUR 1149.6 |
IGF-I, human recombinant |
|||
4119-50MG | Biovision | each | EUR 5064 |
Recombinant Human IGF-1, 15N |
|||
HEGFP-0902 | Cyagen | 10ug | Ask for price |
Związek między poziomami alarmin w surowicy a wskaźnikami specyficznymi dla choroby u pacjentów z zapaleniem naczyń związanym z cytoplazmatycznymi przeciwciałami przeciw neutrofilom
Background/purpose: We evaluated the connection between serum alarmin ranges and disease-specific indices in sufferers with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Sufferers and strategies: Sera and information from 79 sufferers had been utilized. For AAV-specific indices, Birmingham vasculitis exercise rating (BVAS), five-factor rating (FFS), and vasculitis harm index (VDI) had been collected and serum ranges of 4 alarmins (hepatoma-derived progress issue, excessive mobility group field protein 1, S100A9, and S100A12) had been measured utilizing enzyme-linked immunosorbent assay. Associations between alarmin ranges, AAV-specific indices, and inflammatory laboratory markers had been assessed.
Outcomes: S100A9 ranges had been considerably correlated with C-reactive protein ranges (r=0.316, p=0.005) and S100A12 ranges correlated with VDI (r=0.232, p=0.040), which was constant in a subgroup of sufferers with myeloperoxidase (perinuclear)-ANCA positivity. No different associations had been discovered between alarmin ranges and BVAS, FFS, and VDI.
Conclusion: The serum S100A12 degree was related to organ harm in AAV, particularly in myeloperoxidase (perinuclear)-ANCA-positive sufferers.
Zapalenie skórno-mięśniowe z dodatnim przeciwciałem anty-MDA5 z szybko postępującą śródmiąższową chorobą płuc: opis dwóch przypadków
Melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) shows distinctive cutaneous and pathologic options. We describe two circumstances of myositis-associated quickly progressive interstitial lung illness (RP-ILD).
The sufferers had been two girls from Kerala, India. Each sufferers had anti-MDA5 antibody-positive myositis. Each sufferers offered with RP-ILD with none scientific options of myositis and succumbed to their sickness regardless of aggressive medical therapy. Anti-MDA5-antibody-positive DM is characterised by amyopathic illness with quickly progressive and deadly ILD.
Charakterystyka przeciwciał monoklonalnych przeciw tężcowi jako pierwszy krok w kierunku opracowania testu immunologicznego na siłę szczepionki in vitro
Batch launch testing for human and veterinary tetanus vaccines nonetheless depends closely on strategies that contain animals, notably for efficiency testing. The amount and high quality of tetanus antigen current in these merchandise is of utmost significance for product security and scientific impact. Immunochemical strategies that measure consistency of antigen content material and high quality, doubtlessly as an indicator of efficiency, may very well be a better option and negate the necessity for an in vivo efficiency check. These immunochemical strategies require at the least one nicely characterised monoclonal antibody (mAb) that’s particular for the goal antigen. On this paper we report the outcomes of the excellent characterisation of a panel of mAbs towards tetanus with a view to pick antibodies that can be utilized for improvement of an in vitro efficiency immunoassay.
We’ve assessed binding of the antibodies to native antigen (toxin), detoxified antigen (toxoid), adsorbed antigen and heat-altered antigen. Antibody perform was decided utilizing an in-house cell-based neutralisation assay to assist prior in vivo efficiency information that was obtainable for some, however not all, of the antibodies. As well as, antibody affinity was measured, and epitope competitors evaluation was carried out to establish pairs of antibodies that may very well be deployed in a sandwich immunoassay format. Not all characterisation assessments offered proof of “superiority” of 1 mAb over one other, however collectively the outcomes from all characterisation research allowed for choice of an antibody pair to be taken ahead to assay improvement.
Opis przypadku: autoimmunologiczne zapalenie mózgu związane z przeciwciałami dekarboksylazy kwasu przeciwglutaminowego: seria przypadków pediatrycznych
Background: Antibodies towards glutamic acid decarboxylase (GAD) are related to varied neurologic circumstances described in sufferers, together with stiff particular person syndrome, cerebellar ataxia, refractory epilepsy, and limbic and extralimbic encephalitis. There have been some case stories and investigations relating to anti-GAD65 antibody-associated encephalitis in grownup populations, however pediatric circumstances are uncommon. We retrospectively analyzed the scientific information of three anti-GAD65 antibody-positive sufferers to discover the range and scientific options of anti-GAD65 antibody-associated pediatric autoimmune encephalitis.
Strategies: The scientific information of a sequence of three sufferers optimistic for anti-GAD65 antibody had been retrospectively analyzed. GAD65 antibodies had been decided in serum and CSF utilizing a cell-based assay.
Outcomes: All three sufferers had been feminine, and the onset ages had been four years and 9 months, 6 years, and 16 years previous. Their scientific phenotypes included autoimmune limbic encephalitis, extralimbic encephalitis, and encephalitis combining limbic and extralimbic encephalitis. The scientific signs included seizures, reminiscence deficits, drowsiness, dysautonomia, and headache. All sufferers had irregular carinal MRI and EEG. All sufferers obtained immunotherapy and had transiently good responsiveness, however one affected person then skilled relapse. In follow-up, one affected person with extralimbic encephalitis recovered utterly, whereas two sufferers with limbic involvement had poor outcomes with refractory focal epilepsy.
Conclusion: Along with limbic encephalitis, extralimbic encephalitis can also be an necessary phenotype in sufferers who’re optimistic for anti-GAD65 antibodies. Early analysis and immunotherapy can enhance the signs. Nevertheless, sufferers with limbic encephalitis typically have refractory epilepsy within the continual section and have a poor long-term final result.
CXCL7 Recombinant Protein |
|||
92-388 | ProSci | 0.05 mg | EUR 437.1 |
Description: Human Chemokine (C-X-C motif) Ligand 7 (CXCL7), also known as neutrophil activating peptide 2 (NAP-2), is a member of the CXC chemokines containing an ELR domain (Glu-Leu-Arg tripeptide motif). Similar to other ELR domain containing CXC chemokines, such as IL-8 and the GRO proteins, CXCL7 binds CXCR2, chemoattracts and activates neutrophils. CXCL7, Connective Tissue Activating Protein III (CTAPIII) and beta thrombogulin ( beta TG), are proteolytically processed carboxylterminal fragments of platelet basic protein (PBP) which is found in the alphagranules of human platelets. Although CTAPIII, beta TG, and PBP represent amino-terminal extended variants of NAP2 and possess the same CXC chemokine domains, these proteins do not exhibit CXCL7/NAP2 activity. CXCL7 induces cell migration through the G-protein-linked receptor CXCR-2. |
NAP-2 Antibody / CXCL7 / PPBP |
|||
RQ4113 | NSJ Bioreagents | 100 ug | EUR 356.15 |
Description: Chemokine (C-X-C motif) ligand 7 (CXCL7), also known as NAP2 or Pro-Platelet basic protein (PPBP), is a human gene. The protein encoded by this gene is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells. Furthermore, the protein is an antimicrobial protein with bactericidal and antifungal activity. |
NAP-2/CXCL7, Rat |
|||
HY-P7269 | MedChemExpress | 50ug | EUR 639.6 |
NAP-2, CXCL7, rat |
|||
RC352-18 | Bio Basic | 2ug | EUR 125.26 |
NAP-2/CXCL7, Human |
|||
HY-P7268 | MedChemExpress | 50ug | EUR 639.6 |
NAP-2, CXCL7, human |
|||
RC312-18 | Bio Basic | 2ug | EUR 125.26 |
Human CXCL7 ELISA Kit |
|||
LF-EK50893 | Abfrontier | 1×96T | EUR 777.6 |
CXCL7 ELISA KIT|Human |
|||
EF001450 | Lifescience Market | 96 Tests | EUR 826.8 |
ELISA kit for Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) |
|||
E-EL-M1269 | Elabscience Biotech | 1 plate of 96 wells | EUR 640.8 |
Description: A sandwich ELISA kit for quantitative measurement of Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant |
Human CXCL7 Antibody (Biotin Conjugate) |
|||
32852-05121 | AssayPro | 150 ug | EUR 442.8 |
ELISA kit for Human CXCL7 |
|||
EK5304 | SAB | 96 tests | EUR 663.6 |
Description: Enzyme-linked immunosorbent assay kit for quantification of Human CXCL7 in samples from serum, plasma, tissue homogenates and other biological fluids. |
Recombinant Rat NAP-2/CXCL7 |
|||
RECXP-0701 | Cyagen | 10ug | Ask for price |
Human CXCL7 AssayLite Antibody (RPE Conjugate) |
|||
32852-05151 | AssayPro | 150 ug | EUR 513.6 |
Human CXCL7 AssayLite Antibody (APC Conjugate) |
|||
32852-05161 | AssayPro | 150 ug | EUR 513.6 |
Human CXCL7 AssayMax ELISA Kit |
|||
EC2270-1 | AssayPro | 96 Well Plate | EUR 572.4 |
Human CXCL7 PicoKine ELISA Kit |
|||
EK0729 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of human CXCL7 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA). |
Human CXCL7 AssayLite Antibody (FITC Conjugate) |
|||
32852-05141 | AssayPro | 150 ug | EUR 513.6 |
Recombinant Human NAP-2 (CXCL7) |
|||
HECXP-0701 | Cyagen | 10ug | Ask for price |
Human CXCL7 AssayLite Antibody (PerCP Conjugate) |
|||
32852-05171 | AssayPro | 150 ug | EUR 565.2 |
Neutrophil Activating Protein-2 (CXCL7) Antibody |
|||
20-abx137035 | Abbexa |
|
|
Nori® Canine CXCL7 ELISA Kit |
|||
GR115398 | Genorise Scientific | 96-well | EUR 461 |
Nori Equine CXCL7/NAP2 ELISA Kit |
|||
GR106909 | Genorise Scientific | 96-well | EUR 461 |
Rat PPBP/CXCL7 PicoKine ELISA Kit |
|||
EK0731 | BosterBio | 96 wells | EUR 510 |
Description: For Quantitative Detection of rat CXCL7 in cell culture supernates, serum and plasma (heparin, EDTA). |
NAP-2/CXCL7 (CHO-expressed), Human |
|||
HY-P7267 | MedChemExpress | 50ug | EUR 596.4 |
Recombinant Human CXCL7/NAP-2 Protein |
|||
RP00829 | Abclonal | 10 μg | EUR 265.2 |
ThymusChemokine‑1/CXCL7 (CHO-expressed), Rat |
|||
HY-P7301 | MedChemExpress | 10ug | EUR 349.2 |
Nori® Human CXCL7-NAP2 ELISA Kit |
|||
GR106282 | Genorise Scientific | 96-well | EUR 461 |
Neutrophil Activating Protein-2 (CXCL7) Protein |
|||
20-abx261559 | Abbexa |
|
|
Neutrophil Activating Protein-2 (CXCL7) Protein |
|||
20-abx261561 | Abbexa |
|
|
Human CXCL7(Platelet basic protein) ELISA Kit |
|||
EH0007 | FN Test | 96T | EUR 681.12 |
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 9.375pg/ml |
Rabbit Anti Mouse Cxcl1 Polyclonal Antibody |
|||
CPBT-65100RM | Creative Diagnostics | 0.1 mg | EUR 1057.2 |
Human CXCL7 EZ-Set™ ELISA Kit (DIY Antibody Pairs) |
|||
EZ0729 | BosterBio | 5 plates/kit | EUR 321.6 |
Description: For the development of sandwich ELISA kit to measure human CXCL7 in cell culture supernates, cell lysates, tissue homogenates, serum and plasma (heparin, EDTA). |
Recombinant Rat Neutrophil Activating Protein-2 (CXCL7) |
|||
7-02065 | CHI Scientific | 2µg | Ask for price |
Recombinant Rat Neutrophil Activating Protein-2 (CXCL7) |
|||
7-02066 | CHI Scientific | 10µg | Ask for price |
Recombinant Rat Neutrophil Activating Protein-2 (CXCL7) |
|||
7-02067 | CHI Scientific | 1mg | Ask for price |
Rat Platelet Basic Protein / CXCL7 (PPBP) ELISA Kit |
|||
abx255841-96tests | Abbexa | 96 tests | EUR 801.6 |
Pig Platelet Basic Protein / CXCL7 (PPBP) ELISA Kit |
|||
abx511493-96tests | Abbexa | 96 tests | EUR 1093.2 |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7) |
|||
7-02059 | CHI Scientific | 2µg | Ask for price |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7) |
|||
7-02060 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7) |
|||
7-02061 | CHI Scientific | 1mg | Ask for price |
Human Platelet Basic Protein / CXCL7 (PPBP) ELISA Kit |
|||
abx252283-96tests | Abbexa | 96 tests | EUR 801.6 |
Neutrophil Activating Protein-2 (CXCL7), 95 a.a. Protein |
|||
20-abx260678 | Abbexa |
|
|
Recombinant (E.Coli) Human Neutrophil Activating Protein-2 (CXCL7) |
|||
RP-1008 | Alpha Diagnostics | 10 ug | EUR 343.2 |
Human Thromboglobulin, Beta (bTG/PBP/CXCL7/NAP2) CLIA Kit |
|||
abx197774-96tests | Abbexa | 96 tests | EUR 990 |
Mouse Anti-Human CXCL13 monoclonal antibody, clone JID662 |
|||
CABT-L2832-100uL500uL | Creative Diagnostics | 100 uL, 500 uL | EUR 602.4 |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7), 95 a.a. |
|||
7-02062 | CHI Scientific | 2µg | Ask for price |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7), 95 a.a. |
|||
7-02063 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Neutrophil Activating Protein-2 (CXCL7), 95 a.a. |
|||
7-02064 | CHI Scientific | 1mg | Ask for price |
ELISA kit for Rat ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) |
|||
E-EL-R1087 | Elabscience Biotech | 1 plate of 96 wells | EUR 640.8 |
Description: A sandwich ELISA kit for quantitative measurement of Rat ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant |
ELISA kit for Human ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) |
|||
E-EL-H1007 | Elabscience Biotech | 1 plate of 96 wells | EUR 640.8 |
Description: A sandwich ELISA kit for quantitative measurement of Human ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Plasma |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-1mg |
|||
QP8641-ec-1mg | EnQuireBio | 1mg | EUR 1958.4 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-10ug |
|||
QP8641-ec-10ug | EnQuireBio | 10ug | EUR 240 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-50ug |
|||
QP8641-ec-50ug | EnQuireBio | 50ug | EUR 315.6 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-100ug |
|||
QP8641-ec-100ug | EnQuireBio | 100ug | EUR 489.6 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-200ug |
|||
QP8641-ec-200ug | EnQuireBio | 200ug | EUR 760.8 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-500ug |
|||
QP8641-ec-500ug | EnQuireBio | 500ug | EUR 1272 |
Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-2ug |
|||
QP10285-ec-2ug | EnQuireBio | 2ug | EUR 184.8 |
Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2 |
|||
C056-10ug | Novoprotein | 10ug | EUR 242.4 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2 |
|||
C056-1mg | Novoprotein | 1mg | EUR 2739.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2 |
|||
C056-500ug | Novoprotein | 500ug | EUR 1935.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2 |
|||
C056-50ug | Novoprotein | 50ug | EUR 595.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-10ug |
|||
QP10285-ec-10ug | EnQuireBio | 10ug | EUR 348 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-2ug |
|||
QP10212-ec-2ug | EnQuireBio | 2ug | EUR 184.8 |
Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-100ug |
|||
QP10285-ec-100ug | EnQuireBio | 100ug | EUR 1413.6 |
Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-250ug |
|||
QP10285-ec-250ug | EnQuireBio | 250ug | EUR 2480.4 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-10ug |
|||
QP10212-ec-10ug | EnQuireBio | 10ug | EUR 348 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-100ug |
|||
QP10212-ec-100ug | EnQuireBio | 100ug | EUR 1185.6 |
Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-250ug |
|||
QP10212-ec-250ug | EnQuireBio | 250ug | EUR 2077.2 |
Polyclonal (Mouse) Cxcl12 Antibody |
|||
APR10977G | Leading Biology | 0.1ml | EUR 633.6 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human (Mouse) Cxcl12 . This antibody is tested and proven to work in the following applications: |
NAP-2 Neutrophil Activating Protein-2 Rat Recombinant Protein (CXCL7) |
|||
PROTQ99ME0 | BosterBio | Regular: 10ug | EUR 380.4 |
Description: NAP-2 Rat Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 62 amino acids and having a molecular mass of 6.8kDa.;The NAP 2 is purified by proprietary chromatographic techniques. |
NAP-2 Neutrophil Activating Protein-2 Human Recombinant Protein (CXCL7) |
|||
PROTP02775 | BosterBio | Regular: 10ug | EUR 380.4 |
Description: Neutrophil Activating Protein-2 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 70 amino acids and having a molecular mass of 7609 Dalton. ;The NAP-2 is purified by proprietary chromatographic techniques. |
CXCL16, Mouse |
|||
HY-P7151 | MedChemExpress | 10ug | EUR 321.6 |
Genorise® Mouse CXCL10 Polyclonal Antibody |
|||
GR131005 | Genorise Scientific | 100 µg | EUR 398 |
Mouse CXCL10 ELISA Kit |
|||
55R-1745 | Fitzgerald | 1 kit | EUR 781.2 |
Description: ELISA kit for detection of CXCL10 in the research laboratory |
Mouse CXCL16 ELISA Kit |
|||
55R-1746 | Fitzgerald | 1 kit | EUR 781.2 |
Description: ELISA kit for detection of CXCL16 in the research laboratory |
Mouse CXCL16 ELISA kit |
|||
55R-2086 | Fitzgerald | 96 tests | EUR 854.4 |
Description: ELISA Kit for detection of CXCL16 in the research laboratory |
Mouse CXCL16 ELISA Kit |
|||
EMC0858 | Abclonal | 96Tests | EUR 625.2 |
Mouse CXCL16 ELISA kit |
|||
LF-EK50573 | Abfrontier | 1×96T | EUR 777.6 |
Mouse CXCL10 ELISA Kit |
|||
STJ150228 | St John's Laboratory | 1 kit | EUR 494.4 |
Description: The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of IP-10/CXCL10 in Mouse serum, plasma and other biological fluids |
CXCL3, Mouse |
|||
HY-P7153 | MedChemExpress | 50ug | EUR 804 |
Recombinant Mouse CXCL16 |
|||
7-01804 | CHI Scientific | 5µg | Ask for price |
Recombinant Mouse CXCL16 |
|||
7-01805 | CHI Scientific | 25µg | Ask for price |
Recombinant Mouse CXCL16 |
|||
7-01806 | CHI Scientific | 1mg | Ask for price |
CXCL16, murine (mouse) |
|||
RC332-27 | Bio Basic | 5ug | EUR 125.26 |
IP-10/CXCL10, Mouse |
|||
HY-P7227 | MedChemExpress | 50ug | EUR 639.6 |
CXCL16 protein (mouse) |
|||
30R-AC078 | Fitzgerald | 25 ug | EUR 327.6 |
Description: Purified recombinant Mouse CXCL16 protein |
Mouse CXCL13/BLC ELISA Kit |
|||
LF-EK50896 | Abfrontier | 1×96T | EUR 777.6 |
ELISA kit for Mouse CXCL16 |
|||
EK5311 | SAB | 96 tests | EUR 663.6 |
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse CXCL16 in samples from serum, plasma, tissue homogenates and other biological fluids. |
Mouse CXCL16 shRNA Plasmid |
|||
20-abx975400 | Abbexa |
|
|
Mouse CXCL15 shRNA Plasmid |
|||
20-abx972610 | Abbexa |
|
|